Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare

1,437 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OCUL Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Ocular

Therapeutix

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$17.33

▲(40.32% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $17.33 with a high forecast of $21.00 and a low forecast of $14.00. The average price target represents a 40.32% change from the last price of $12.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","9.25":"$9.25","13.5":"$13.5","17.75":"$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.618461538461538,13.316923076923077,14.015384615384615,14.713846153846154,15.412307692307692,16.11076923076923,16.80923076923077,17.50769230769231,18.206153846153846,18.904615384615383,19.603076923076923,20.301538461538463,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.336153846153845,12.752307692307692,13.168461538461537,13.584615384615384,14.00076923076923,14.416923076923077,14.833076923076922,15.249230769230769,15.665384615384614,16.08153846153846,16.497692307692304,16.91384615384615,{"y":17.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.08,12.24,12.4,12.56,12.72,12.879999999999999,13.04,13.2,13.36,13.52,13.68,13.84,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.00

Average Price Target$17.33

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$12.5

Hold

1.21%

Upside

Reiterated

07/26/25

Ocular Therapeutix's stock score is driven by strong market momentum, despite being overbought, and significant revenue growth. However, the company's financial health is compromised by persistent losses and negative cash flows, impacting its valuation.

Dane LeoneRaymond James

Raymond James

$19

Buy

53.85%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Biren AminPiper Sandler

Piper Sandler

$21

Buy

70.04%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Greg HarrisonScotiabank

Scotiabank

$22

Buy

78.14%

Upside

Reiterated

05/29/25

Scotiabank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

Yi ChenH.C. Wainwright

H.C. Wainwright

$15

Buy

21.46%

Upside

Reiterated

05/29/25

Ocular Therapeutix's Promising Clinical Trials and Strategic Advancements Justify Buy Rating

William MaughanClear Street

Clear Street

$18

Buy

45.75%

Upside

Reiterated

05/28/25

Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

05/28/25

Ocular Therapeutix's Promising Developments and Strategic Execution Justify Buy Rating

Serge BelangerNeedham

Needham

$14

Buy

13.36%

Upside

Reiterated

05/28/25

Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

Tazeen AhmadBank of America Securities

Bank of America Securities

$17

Buy

37.65%

Upside

Reiterated

05/19/25

Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities

Tara BancroftTD Cowen

TD Cowen

$14

Buy

13.36%

Upside

Reiterated

05/05/25

Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement

Lisa WalterRBC Capital

RBC Capital

$17

Buy

37.65%

Upside

Reiterated

05/05/25

RBC Capital Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Jonathan WollebenCitizens JMP

Citizens JMP

$19

Buy

53.85%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Colleen M. KusyRobert W. Baird

Robert W. Baird

$17

Buy

37.65%

Upside

Reiterated

12/03/24

Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$12.5

Hold

1.21%

Upside

Reiterated

07/26/25

Dane LeoneRaymond James

Raymond James

$19

Buy

53.85%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Biren AminPiper Sandler

Piper Sandler

$21

Buy

70.04%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Greg HarrisonScotiabank

Scotiabank

$22

Buy

78.14%

Upside

Reiterated

05/29/25

Scotiabank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

Yi ChenH.C. Wainwright

H.C. Wainwright

$15

Buy

21.46%

Upside

Reiterated

05/29/25

Ocular Therapeutix's Promising Clinical Trials and Strategic Advancements Justify Buy Rating

William MaughanClear Street

Clear Street

$18

Buy

45.75%

Upside

Reiterated

05/28/25

Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

05/28/25

Ocular Therapeutix's Promising Developments and Strategic Execution Justify Buy Rating

Serge BelangerNeedham

Needham

$14

Buy

13.36%

Upside

Reiterated

05/28/25

Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

Tazeen AhmadBank of America Securities

Bank of America Securities

$17

Buy

37.65%

Upside

Reiterated

05/19/25

Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities

Tara BancroftTD Cowen

TD Cowen

$14

Buy

13.36%

Upside

Reiterated

05/05/25

Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement

Lisa WalterRBC Capital

RBC Capital

$17

Buy

37.65%

Upside

Reiterated

05/05/25

RBC Capital Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Jonathan WollebenCitizens JMP

Citizens JMP

$19

Buy

53.85%

Upside

Reiterated

04/23/25

Colleen M. KusyRobert W. Baird

Robert W. Baird

$17

Buy

37.65%

Upside

Reiterated

12/03/24

Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

1 Month

xxx

Success Rate

9/21 ratings generated profit

Average Return

+5.94%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +5.94% per trade.

3 Months

xxx

Success Rate

11/21 ratings generated profit

Average Return

+8.78%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +8.78% per trade.

1 Year

Yi ChenH.C. Wainwright

Success Rate

17/22 ratings generated profit

Average Return

+51.40%

reiterated a buy rating 2 days ago

Copying Yi Chen's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +51.40% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+110.18%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +110.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OCUL has received 5 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 17.33.

Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.38 with a range of -$0.42 to -$0.34. The previous quarter’s EPS was -$0.39. OCUL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $14.60M with a range of $12.60M to $19.00M. The previous quarter’s sales results were $13.46M. OCUL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Ocular Therapeutix Inc’s 12-month average price target is 17.33.

What is OCUL’s upside potential, based on the analysts’ average price target?

Ocular Therapeutix Inc has 40.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OCUL a Buy, Sell or Hold?

Ocular Therapeutix Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ocular Therapeutix Inc’s price target?

The average price target for Ocular Therapeutix Inc is 17.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $14.00. The average price target represents 40.32% Increase from the current price of $12.35.

What do analysts say about Ocular Therapeutix Inc?

Ocular Therapeutix Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of OCUL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

OCUL Analyst Ratings

OCUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ocular Therapeutix

OCUL Analyst Recommendation Trends

OCUL Financial Forecast

OCUL Earnings Forecast

OCUL Sales Forecast

OCUL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts